Search Results
Search for other papers by Eduardo Vilar in
Google Scholar
PubMed
Search for other papers by Ramón Salazar in
Google Scholar
PubMed
Search for other papers by Jose Pérez-García in
Google Scholar
PubMed
Search for other papers by Javier Cortes in
Google Scholar
PubMed
Search for other papers by Kjell Öberg in
Google Scholar
PubMed
Search for other papers by Josep Tabernero in
Google Scholar
PubMed
Introduction Neuroendocrine tumors (NETs) of the digestive tract include different subsets of malignancies, such as pancreatic endocrine tumors (PETs), carcinoid tumors (CTs), and other poorly differentiated gastroentero-pancreatic
Department of Medical Oncology, Departments of Environmental Health, Biostatistics, Dana-Farber Cancer Institute, Dana 1250, 450 Brookline Avenue, Boston, Massachusetts 02215, USA
Search for other papers by Monica Ter-Minassian in
Google Scholar
PubMed
Search for other papers by Jennifer A Chan in
Google Scholar
PubMed
Search for other papers by Susanne M Hooshmand in
Google Scholar
PubMed
Search for other papers by Lauren K Brais in
Google Scholar
PubMed
Search for other papers by Anastassia Daskalova in
Google Scholar
PubMed
Search for other papers by Rachel Heafield in
Google Scholar
PubMed
Search for other papers by Laurie Buchanan in
Google Scholar
PubMed
Search for other papers by Zhi Rong Qian in
Google Scholar
PubMed
Search for other papers by Charles S Fuchs in
Google Scholar
PubMed
Search for other papers by Xihong Lin in
Google Scholar
PubMed
Search for other papers by David C Christiani in
Google Scholar
PubMed
Search for other papers by Matthew H Kulke in
Google Scholar
PubMed
gastroenteropancreatic NET; we focused our analyses on two major subgroups: small bowel NET and panNET. We found that delays in diagnosis from initial symptoms were shorter than previously reported. We also noted that median disease-free and OS times were shorter than
Search for other papers by Thomas Yang Sun in
Google Scholar
PubMed
Search for other papers by Lan Zhao in
Google Scholar
PubMed
Search for other papers by Paul Van Hummelen in
Google Scholar
PubMed
Search for other papers by Brock Martin in
Google Scholar
PubMed
Search for other papers by Kathleen Hornbacker in
Google Scholar
PubMed
Search for other papers by HoJoon Lee in
Google Scholar
PubMed
Division of Biostatistics, Department of Epidemiology and Public Health, Albert Einstein College of Medicine, Bronx, New York, USA
Search for other papers by Li C Xia in
Google Scholar
PubMed
Search for other papers by Sukhmani K Padda in
Google Scholar
PubMed
Stanford Genome Technology Center, Stanford, California, USA
Search for other papers by Hanlee P Ji in
Google Scholar
PubMed
Search for other papers by Pamela Kunz in
Google Scholar
PubMed
Introduction Neuroendocrine neoplasms (NENs) commonly originate from the gastroenteropancreatic (GEP) organs and the lungs but can also arise from most other organs in the body, including the genitourinary tract, head and neck, the gynecologic
Search for other papers by Kimberly Kamp in
Google Scholar
PubMed
Search for other papers by Brenda Gumz in
Google Scholar
PubMed
Search for other papers by Richard A Feelders in
Google Scholar
PubMed
Search for other papers by Dik J Kwekkeboom in
Google Scholar
PubMed
Search for other papers by Gregory Kaltsas in
Google Scholar
PubMed
Search for other papers by Frederico P Costa in
Google Scholar
PubMed
Search for other papers by Wouter W de Herder in
Google Scholar
PubMed
Introduction Neuroendocrine tumors (NETs) form a heterogeneous group of relatively rare neoplasms that originate from different types of neuroendocrine cells ( Modlin et al . 2008 ). The incidence and prevalence of gastroenteropancreatic NETs (GEP
Search for other papers by Andrea Frilling in
Google Scholar
PubMed
Search for other papers by Goran Åkerström in
Google Scholar
PubMed
Search for other papers by Massimo Falconi in
Google Scholar
PubMed
Search for other papers by Marianne Pavel in
Google Scholar
PubMed
Search for other papers by Jose Ramos in
Google Scholar
PubMed
Search for other papers by Mark Kidd in
Google Scholar
PubMed
Search for other papers by Irvin Mark Modlin in
Google Scholar
PubMed
Introduction Gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) are also referred to as neuroendocrine tumors (NETs) or ‘carcinoids’, although this term is archaic and should be discarded in favor of a nomenclature reflective of specific
Search for other papers by Maria Chiara Zatelli in
Google Scholar
PubMed
Search for other papers by Mirella Torta in
Google Scholar
PubMed
Search for other papers by Antonette Leon in
Google Scholar
PubMed
Search for other papers by Maria Rosaria Ambrosio in
Google Scholar
PubMed
Search for other papers by Massimo Gion in
Google Scholar
PubMed
Search for other papers by Paola Tomassetti in
Google Scholar
PubMed
Search for other papers by Filippo De Braud in
Google Scholar
PubMed
Search for other papers by Gianfranco Delle Fave in
Google Scholar
PubMed
Search for other papers by Luigi Dogliotti in
Google Scholar
PubMed
Search for other papers by Ettore C degli Uberti in
Google Scholar
PubMed
, an Italian multicenter observational study has been performed in a large series of gastroenteropancreatic (GEP) NET patients and healthy controls to assess the usefulness of CgA determination for the diagnosis of sporadic GEP NETs and to establish the
LuGenIum Consortium for Independent Research, Milan, Rotterdam, Bad Berka, London
Search for other papers by Lisa Bodei in
Google Scholar
PubMed
Emeritus Professor Gastroenterological Surgery, Yale University, School of Medicine, New Haven, Connecticut, USA
Search for other papers by Irvin M Modlin in
Google Scholar
PubMed
Search for other papers by Markus Luster in
Google Scholar
PubMed
Search for other papers by Flavio Forrer in
Google Scholar
PubMed
Search for other papers by Marta Cremonesi in
Google Scholar
PubMed
Search for other papers by Rodney J Hicks in
Google Scholar
PubMed
Search for other papers by Samer Ezziddin in
Google Scholar
PubMed
Search for other papers by Mark Kidd in
Google Scholar
PubMed
Search for other papers by Arturo Chiti in
Google Scholar
PubMed
Introduction It is now widely accepted that peptide receptor radionuclide therapy (PRRT) is an effective treatment for inoperable or metastatic neuroendocrine tumors (NETs), particularly well-differentiated gastroenteropancreatic (GEP) or
Aix-Marseille Université, Molecular Biology Laboratory, Aix-Marseille Université, Department of Internal Medicine and Center of Excellence for Biomedical Research, Endocrinology Department, Oncology Department, Surgery Department, Biopathology Department, Pathology Laboratory, Surgery Department, Department of Integrative Biology and Pharmacology, CNRS, CRN2M‐UMR 7286, Faculté de Médecine, Secteur Nord – CS80011, 51, Bd Pierre Dramard, 13344 Marseille Cedex 15, France
Search for other papers by Amira Mohamed in
Google Scholar
PubMed
Search for other papers by Marie-Pierre Blanchard in
Google Scholar
PubMed
Search for other papers by Manuela Albertelli in
Google Scholar
PubMed
Search for other papers by Federica Barbieri in
Google Scholar
PubMed
Aix-Marseille Université, Molecular Biology Laboratory, Aix-Marseille Université, Department of Internal Medicine and Center of Excellence for Biomedical Research, Endocrinology Department, Oncology Department, Surgery Department, Biopathology Department, Pathology Laboratory, Surgery Department, Department of Integrative Biology and Pharmacology, CNRS, CRN2M‐UMR 7286, Faculté de Médecine, Secteur Nord – CS80011, 51, Bd Pierre Dramard, 13344 Marseille Cedex 15, France
Search for other papers by Thierry Brue in
Google Scholar
PubMed
Search for other papers by Patricia Niccoli in
Google Scholar
PubMed
Search for other papers by Jean-Robert Delpero in
Google Scholar
PubMed
Search for other papers by Genevieve Monges in
Google Scholar
PubMed
Search for other papers by Stephane Garcia in
Google Scholar
PubMed
Search for other papers by Diego Ferone in
Google Scholar
PubMed
Search for other papers by Tullio Florio in
Google Scholar
PubMed
Aix-Marseille Université, Molecular Biology Laboratory, Aix-Marseille Université, Department of Internal Medicine and Center of Excellence for Biomedical Research, Endocrinology Department, Oncology Department, Surgery Department, Biopathology Department, Pathology Laboratory, Surgery Department, Department of Integrative Biology and Pharmacology, CNRS, CRN2M‐UMR 7286, Faculté de Médecine, Secteur Nord – CS80011, 51, Bd Pierre Dramard, 13344 Marseille Cedex 15, France
Search for other papers by Alain Enjalbert in
Google Scholar
PubMed
Search for other papers by Vincent Moutardier in
Google Scholar
PubMed
Search for other papers by Agnes Schonbrunn in
Google Scholar
PubMed
Search for other papers by Corinne Gerard in
Google Scholar
PubMed
Aix-Marseille Université, Molecular Biology Laboratory, Aix-Marseille Université, Department of Internal Medicine and Center of Excellence for Biomedical Research, Endocrinology Department, Oncology Department, Surgery Department, Biopathology Department, Pathology Laboratory, Surgery Department, Department of Integrative Biology and Pharmacology, CNRS, CRN2M‐UMR 7286, Faculté de Médecine, Secteur Nord – CS80011, 51, Bd Pierre Dramard, 13344 Marseille Cedex 15, France
Search for other papers by Anne Barlier in
Google Scholar
PubMed
Aix-Marseille Université, Molecular Biology Laboratory, Aix-Marseille Université, Department of Internal Medicine and Center of Excellence for Biomedical Research, Endocrinology Department, Oncology Department, Surgery Department, Biopathology Department, Pathology Laboratory, Surgery Department, Department of Integrative Biology and Pharmacology, CNRS, CRN2M‐UMR 7286, Faculté de Médecine, Secteur Nord – CS80011, 51, Bd Pierre Dramard, 13344 Marseille Cedex 15, France
Search for other papers by Alexandru Saveanu in
Google Scholar
PubMed
Introduction Gastroenteropancreatic neuroendocrine tumors (GEP–NETs) constitute a rare group of tumors, with a significant increase in incidence and prevalence in the past few decades ( Oberg 2011 ). GEP–NETs still raise difficult therapeutic
Search for other papers by Tessa Brabander in
Google Scholar
PubMed
Search for other papers by Wouter A van der Zwan in
Google Scholar
PubMed
Search for other papers by Jaap J M Teunissen in
Google Scholar
PubMed
Search for other papers by Boen L R Kam in
Google Scholar
PubMed
Search for other papers by Wouter W de Herder in
Google Scholar
PubMed
Search for other papers by Richard A Feelders in
Google Scholar
PubMed
Search for other papers by Eric P Krenning in
Google Scholar
PubMed
Search for other papers by Dik J Kwekkeboom in
Google Scholar
PubMed
for PRRT are Yttrium-90 and Lutetium-177, linked to [DOTA 0 ,Tyr 3 ]octreotide ( 90 Y-DOTATOC) or [DOTA 0 ,Tyr 3 ]octreotate ( 177 Lu-DOTATATE), respectively. The objective response rate in patients with gastroenteropancreatic neuroendocrine tumours
Search for other papers by Wouter T Zandee in
Google Scholar
PubMed
Search for other papers by Kimberly Kamp in
Google Scholar
PubMed
Search for other papers by Roxanne C van Adrichem in
Google Scholar
PubMed
Search for other papers by Richard A Feelders in
Google Scholar
PubMed
Search for other papers by Wouter W de Herder in
Google Scholar
PubMed
chromogranin A as marker for survival in patients with metastatic endocrine gastroenteropancreatic tumors . Clinical Gastroenterology and Hepatology 6 820 – 827 . ( doi:10.1016/j.cgh.2008.02.052 ) Barclay TH Schapira DV 1983 Malignant tumors